A lot more than just a good ss here (50 m A/S, 21,
Post# of 20
Posted On: 01/06/2014 8:16:55 PM
A lot more than just a good ss here (50 m A/S, 21,490,621 O/S):
Compare the last 10q (Nov. 2013) to the prior years' (Nov. 2012):
Deferred revenues up 10x from last year, to $222,000
Inventories up 38%
Loss from operations $95,000 vs $239,000 last year
Product sales $456,000 vs $331,000 last year
Royalty income $115,000 vs $120,000 last year
Accounts receivable $215,000 vs $137,000 last year
Cost of sales + SG&A $535,000 vs $578,000 last year
"Net cash flows used in operating activities decreased by approximately $343,000, as compared to the prior year period, primarily due to (i) increased product sales and royalty and licensing fees and timely collection of receivables; ii) extended payment terms with certain vendors; and iii) receipt of cash in connection with the amendment of certain license and consulting agreements with a major international developer and manufacturer of medical devices"
So it's clear to see that they've controlled their expenses and are benefiting from economy of scale. Either an increase in royalty income and/or a continued growth in product sales will make ASNB a profitable company, and soon. The trend is looking very good here.
And not a single share added to the outstanding share count, still 21,490,621 outstanding. That gives them at .05 a market cap of $1,074,531. 4 quarters equal to the last would give them $2,284,000 in revenues; I expect continued growth so that number is a conservative estimate from me. A growth company with profits should be valued well above one year's revs, imo.
No convertible debt or toxic financing.
Assets higher than liabilities with their long term debt requiring reasonable and fixed payments.
And a valuable patent (antimicrobials manufactured into their biomaterials to help combat MRSA). In one study on a catheter coated with their Chronoflex C there was not one single infection (of any kind) in over 8,000 days of use.
And sales to Fortune 500 companies.
And a strong presence in China looking to sell to their medical device manufacturers.
Lots to like here, and the possibility that one of the big device manufacturers may gobble them up. They certainly have considered that; check the designation of their preferred stock.
Great buy point here
Compare the last 10q (Nov. 2013) to the prior years' (Nov. 2012):
Deferred revenues up 10x from last year, to $222,000
Inventories up 38%
Loss from operations $95,000 vs $239,000 last year
Product sales $456,000 vs $331,000 last year
Royalty income $115,000 vs $120,000 last year
Accounts receivable $215,000 vs $137,000 last year
Cost of sales + SG&A $535,000 vs $578,000 last year
"Net cash flows used in operating activities decreased by approximately $343,000, as compared to the prior year period, primarily due to (i) increased product sales and royalty and licensing fees and timely collection of receivables; ii) extended payment terms with certain vendors; and iii) receipt of cash in connection with the amendment of certain license and consulting agreements with a major international developer and manufacturer of medical devices"
So it's clear to see that they've controlled their expenses and are benefiting from economy of scale. Either an increase in royalty income and/or a continued growth in product sales will make ASNB a profitable company, and soon. The trend is looking very good here.
And not a single share added to the outstanding share count, still 21,490,621 outstanding. That gives them at .05 a market cap of $1,074,531. 4 quarters equal to the last would give them $2,284,000 in revenues; I expect continued growth so that number is a conservative estimate from me. A growth company with profits should be valued well above one year's revs, imo.
No convertible debt or toxic financing.
Assets higher than liabilities with their long term debt requiring reasonable and fixed payments.
And a valuable patent (antimicrobials manufactured into their biomaterials to help combat MRSA). In one study on a catheter coated with their Chronoflex C there was not one single infection (of any kind) in over 8,000 days of use.
And sales to Fortune 500 companies.
And a strong presence in China looking to sell to their medical device manufacturers.
Lots to like here, and the possibility that one of the big device manufacturers may gobble them up. They certainly have considered that; check the designation of their preferred stock.
Great buy point here
(0)
(0)EKIMAS Corporation (ASNB) Stock Research Links
Scroll down for more posts ▼